CORESTEMCHEMON Inc. Logo

CORESTEMCHEMON Inc.

Develops stem cell therapies and provides non-clinical CRO preclinical services.

166480 | KO

Overview

Corporate Details

ISIN(s):
KR7166480004
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로255번길 24 (삼평동), 성남시

Description

CORESTEMCHEMON Inc. is a biotechnology company operating through two main divisions: a biopharmaceutical unit and a non-clinical Contract Research Organization (CRO) unit. The biopharmaceutical division is dedicated to the research and development of new drugs based on stem cell therapy technology. Its clinical pipeline primarily targets neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), cerebellar ataxia, and multiple sclerosis, as well as autoimmune diseases like systemic lupus erythematosus (SLE) and fibrosis. The non-clinical CRO division provides comprehensive preclinical services, conducting essential toxicity and efficacy evaluations for pharmaceuticals, biopharmaceuticals, cosmetics, and medical devices to support regulatory approval processes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-10 00:00
자기주식처분결과보고서
Korean 22.3 KB
2025-05-14 00:00
분기보고서 (2025.03)
Korean 1.6 MB
2025-05-07 00:00
주요사항보고서(자기주식처분결정)
Korean 30.8 KB
2025-05-02 00:00
주식등의대량보유상황보고서(일반)
Korean 115.7 KB
2025-05-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.5 KB
2025-05-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-04-30 00:00
투자판단관련주요경영사항 (뉴로나타-알주(자가골수유래중간엽줄기세포) 품목허가사항 변경 허가 신청)
Korean 13.6 KB
2025-04-30 00:00
소속부변경
Korean 3.6 KB
2025-04-28 00:00
교환사채(해외교환사채포함)발행후만기전사채취득 (제3회차)
Korean 9.4 KB
2025-04-25 00:00
투자판단관련주요경영사항(임상시험결과) (근위축성측삭경화증(루게릭병) 환자를 대상으로 뉴로나타-알주(자가골수유래중간엽줄기…
Korean 27.4 KB
2025-04-18 00:00
자기주식처분결과보고서
Korean 22.2 KB
2025-04-04 00:00
주식등의대량보유상황보고서(일반)
Korean 114.4 KB
2025-03-28 00:00
정기주주총회결과
Korean 32.0 KB
2025-03-28 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.0 KB
2025-03-26 00:00
주요사항보고서(자기주식처분결정)
Korean 30.8 KB

Automate Your Workflow. Get a real-time feed of all CORESTEMCHEMON Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CORESTEMCHEMON Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CORESTEMCHEMON Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.